Clinical trials: Allogeneic Stem Cell Transplantation
Prostate Cancer
Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients
The primary objective of this study is to compare the duration of survival between patients receiving docetaxel in combination with the GVAX® vaccine for prostate cancer versus patients receiving docetaxel and prednisone…
- Trial name
- NCT00133224
- Testing
- Immunotherapy allogeneic GM-CSF secreting cellular vaccine, Chemotherapy (docetaxel and prednisone)
- Where
- 115 sites in United States, Belgium and 8 more
- Volunteers
- 408 people
- Sponsor
- Cell Genesys
Tennis Elbow
Safety and Efficacy Study of Allogeneic Adipose-derived Stem Cells for Treatment of Lateral Epicondylitis
The objective of this study is to evaluate the safety and efficacy of allogeneic adipose-derived stem cells (ALLO-ASC) in patients with lateral epicondylitis.
- Trial name
- NCT02131077
- Testing
- ALLO-ASC-TI
- Where
- 6 sites in South Korea
- Volunteers
- 30 people
- Sponsor
- Anterogen Co., Ltd.
Parkinson Disease
Clinical Trial for Parkinson's Disease Using Allogeneic HB-adMSCs (Early and Moderate PD)
This is a randomized, double-blind, single center, phase 2 study to assess efficacy and safety of multiple allogeneic HB-adMSCs vs Placebo for the treatment of Parkinson's disease.
- Trial name
- NCT04995081
- Testing
- Biological/Vaccine: Allogeneic HB-adMSCs
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Hope Biosciences Research Foundation
Covid19
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise
This is a Phase 2a randomized, placebo-controlled study designed to investigate the efficacy, safety and tolerability of COVI-MSC in treating post COVID-19 "long haul" pulmonary compromise.
- Trial name
- BR (NCT04992247)
- Testing
- COVI-MSC
- Sponsor
- Sorrento Therapeutics, Inc.
Acute Myeloid Leukemia
A Trial to Evaluate the Safety and Efficacy of NCR300 in Preventing Recurrence of Acute Myeloid Leukemia（AML) After Transplantation
A Trial to Evaluate the Safety and Efficacy of iNK in the Treatment of Subjects for Preventing Recurrence of Acute Myeloid Leukemia After Allogeneic Blood Stem Cell Transplantation.
- Trial name
- NCT06441084
- Testing
- NCR300 injection
- Volunteers
- 15 people
- Sponsor
- Nuwacell Biotechnologies Co., Ltd.
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
CB-012 is an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets C-type lectin-like molecule-1 (CLL-1). This is a Phase 1 study to evaluate the safety, preliminary efficacy, and pharmacokinetics, of CB-012 (the…
- Trial name
- AMpLify (NCT06128044)
- Testing
- CB-012
- Where
- 10 sites in United States
- Volunteers
- 12 people
- Sponsor
- Caribou Biosciences, Inc.
Osteoarthritis of Knee Joint
Allogeneic Mesenchymal Stem Cells for Osteoarthritis
This study is designed to know the safety and efficacy of 2 different doses of mesenchymal stem cells in patients suffering from osteoarthritis of knee joint.
- Trial name
- NCT01448434
- Testing
- Ex- vivo cultured adult allogeneic MSCs, Plasmalyte-A
- Where
- 4 sites in Malaysia
- Volunteers
- 72 people
- Sponsor
- Stempeutics Research Pvt Ltd
cGVHD
Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease
The purpose of this prospective observational study is to collect data from participants who have recently had an allogenic Stem Cell Transplant(alloSCT) and are at risk of Chronic Graft Versus Host Disease(cGVHD)
- Trial name
- THRIVE (NCT05919511)
- Testing
- Non-Interventional
- Where
- 37 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Incyte Corporation
Type1 Diabetes Mellitus
Wharton´s Jelly Derived Mesenchymal Stromal Cell Treatment of Adult Patients Diagnosed With Type I Diabetes
To investigate the safety and tolerance after allogeneic infusion of WJMSCs intravenously in adult patients diagnosed with type 1 diabetes.
- Trial name
- NCT03406585
- Testing
- ProTrans: Allogeneic transplantation with WJMSCs
- Where
- Sweden
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- NextCell Pharma Ab
Graft vs Host Disease
Acute Graft-Versus-Host Disease (aGvHD) Prophylaxis With ATG-Fresenius in Matched Unrelated Donor-Stem Cell Transplantation (MUD-SCT)
The study aim is to evaluate the influence of the anti-T-lymphocyte globulin ATG-Fresenius S given pre-transplant in addition to standard GvHD prophylaxis with cyclosporine A and a short course of methotrexate with respect to…
- Trial name
- NCT00655343
- Testing
- ATG-Fresenius S
- Where
- Germany
- Volunteers
- 202 people
- Sponsor
- Neovii Biotech
Lymphoma, Follicular, Lymphoma, Mantle-Cell
A Phase 1 Study of ADI-001 in B Cell Malignancies
This is a Phase 1 dose escalation study following a 3+3 study design. The purpose of this study is to evaluate the safety and efficacy of ADI-001 in patients with B cell malignancies.
- Conditions
- Lymphoma, Follicular, Lymphoma, Mantle-Cell, Marginal Zone Lymphoma, Primary Mediastinal B-cell Lymphoma
- Trial name
- GLEAN-1 (NCT04735471)
- Testing
- ADI-001, Fludarabine, Cyclophosphamide
- Where
- 10 sites in United States
- Volunteers
- 34 people
- Sponsor
- Adicet Therapeutics
Severe COVID-19 Disease
RAPA-501-Allo Therapy of COVID-19-ARDS
The first-in-human Phase 1 study component will evaluate two dose levels of RAPA-501-ALLO off the shelf cells in patients with COVID-19-related ARDS, with key endpoints of safety, biologic and potential disease-modifying effects.
- Trial name
- NCT04482699
- Testing
- RAPA-501-Allo off-the-shelf Therapy of COVID-19
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Rapa Therapeutics LLC
Relapsed/Refractory Large B Cell Lymphoma
Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy
The purpose of the EXPAND study is to assess the safety and clinical efficacy of ALLO-647 combined with fludarabine and cyclophosphamide compared to fludarabine and cyclophosphamide alone in a lymphodepletion regimen prior to…
- Trial name
- EXPAND (NCT05714345)
- Testing
- ALLO-647, Fludarabine, Cyclophosphamide
- Where
- 2 sites in United States, Belgium
- Volunteers
- 2 people
- Sponsor
- Allogene Therapeutics
Acute GvHD
Exploratory Safety Study of ALD518 in Subjects With Steroid-refractory Acute Graft Versus Host Disease (GVHD)
The purpose of this study is to determine the safe and tolerable, biologically active, and potentially effective doses(s) of ALD518 in subjects with acute GVHD, who have failed to respond to glucocorticosteroids, for further…
- Trial name
- ALD518-010 (NCT01530256)
- Testing
- ALD518
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- CSL Behring
COVID-19, COVID-19 (SARS-CoV-2 Infection)
Evaluation of Safety, Tolerance, and Efficacy of Allogeneic LB-DTK-COV19 in Severe Coronavirus Disease 2019 Patients
The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of allogeneic SARS-CoV-2-Specific T cells (LB-DTK-COV19) in patients with persistent clinical symptoms following a positive SARS-CoV-2 PCR test…
- Trial name
- NCT07709637
- Testing
- LB-DTK-COV19
- Where
- South Korea
- Volunteers
- 1 people
- Sponsor
- LucasBio
Non Hodgkin Lymphoma (NHL), Leukaemia
Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia.
Phase 1 Open-Label Dose-Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ALA-101
- Trial name
- SAPPHIRE (NCT07518329)
- Testing
- ALA-101
- Where
- 5 sites in Australia
- Volunteers
- 46 people
- Sponsor
- Arovella Therapeutics Ltd
Bronchopulmonary Dysplasia
Safety and Efficacy of MSC-EVs in the Prevention of BPD in Extremely Preterm Infants
The phase 1/2 trial aims to evaluate the safety and efficacy of EXOB-001 consisting of extracellular vesicles derived from umbilical cord mesenchymal stromal cells in the prevention of bronchopulmonary dysplasia (BPD) in…
- Trial name
- EVENEW (NCT06279741)
- Testing
- Endotracheopulmonary Instillation, Suspension
- Where
- 8 sites in Belgium, Italy
- Volunteers
- 265 people
- Sponsor
- EXO Biologics S.A.
Graft-versus-host Disease (GVHD)
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
The purpose of this study is to assess Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood…
- Trial name
- NCT06615050
- Testing
- Tacrolimus (Tac), Methotrexate (MTX), Ruxolitinib (Rux)
- Where
- 30 sites in United States
- Volunteers
- 572 people
- Sponsor
- Incyte Corporation
Normal Female Volunteers
Study of Survival Duration for Donor Skin Cells in Skin Biopsy Wounds
The goal for this study is to examine the persistence of growth arrested,allogeneic,male-donor keratinocytes and fibroblasts when applied as product HP802-247 to the surface of acute excisional wounds in health female volunteers…
- Trial name
- NCT01190865
- Testing
- HP802-247
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Healthpoint
Epstein-Barr Virus (EBV) Infections, Lymphoproliferative Disorders
Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies
The primary objective of this protocol is to provide expanded access to tabelecleucel to participants with Epstein-Barr virus-associated diseases and malignancies for whom there are no other appropriate therapeutic options, and…
- Conditions
- Epstein-Barr Virus (EBV) Infections, Lymphoproliferative Disorders, EBV+ Associated Lymphoma, EBV+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)
- Trial name
- NCT02822495
- Testing
- tabelecleucel
- Sponsor
- Atara Biotherapeutics